Investigational drug · Phase 2
AZD5492
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for B-cell Malignancies.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "AZD5492"
First trial start
2024
Sep 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD5492", any sponsor or status.
Conditions studied
As listed on its trial records.
- B-cell Malignancies
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD5492" as an intervention, largest first.
AstraZenecaAstraZeneca (AZN)
NCT06542250 · 174 participants (planned) · Start Sep 18, 2024 · Primary completion Dec 18, 2029
Drug: AZD5492 · For: B-cell Malignancies
Sites: La Jolla, California; Boston, Massachusetts; Rochester, Minnesota · 31 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06916806 · 72 participants (planned) · Start May 1, 2025 · Primary completion May 5, 2027
Drug: AZD5492 · For: Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathies; Rheumatoid Arthritis
Sites: Anniston, Alabama; Birmingham, Alabama; La Jolla, California · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for B-cell Malignancies
- EmavusertibCA-4948Phase 22 trials
Curis, Inc. · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma
- itacitinibINCB039110Phase 22 trials
Incyte · B-Cell Malignancies, Lung Cancer
- parsaclisibINCB050465Phase 22 trials
Incyte · Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma, B-Cell Malignancies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.